ScholarIQanswers from OpenAlex
University of Virginia Cancer Center
InstitutionResearch output, impact & collaborations
University of Virginia Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about University of Virginia Cancer Center?
ScholarIQrecord summary
University of Virginia Cancer Center is a research organisation in Charlottesville. OpenAlex records 656 works and 34,558 citations for it. 106 researchers list it as their most recent affiliation.
How many works does University of Virginia Cancer Center have?
ScholarIQindexed works
University of Virginia Cancer Center has 656 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does University of Virginia Cancer Center have?
ScholarIQcitation count
University of Virginia Cancer Center has 34,558 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at University of Virginia Cancer Center?
ScholarIQresearcher count
University of Virginia Cancer Center has 106 researchers in the ScholarIQ index.
What is the average h-index at University of Virginia Cancer Center?
ScholarIQavg h-index
University of Virginia Cancer Center has an average h-index of 63 in OpenAlex.
What is the ROR of University of Virginia Cancer Center?
ScholarIQror
The ROR for University of Virginia Cancer Center is on the source record.
What is the OpenAlex record for University of Virginia Cancer Center?
ScholarIQopenalex
The OpenAlex for University of Virginia Cancer Center is on the source record.
Who are the most-cited researchers behind University of Virginia Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on University of Virginia Cancer Center?
ScholarIQmost cited works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Partitioning heritability by functional annotation using genome-wide association summary statistics
Hilary K. Finucane, Brendan Bulik‐Sullivan, Alexander Gusev, Gosia Trynka, Yakir Reshef, Po‐Ru Loh, Verneri Anttila, Han Xu, Chongzhi Zang, Kyle Kai-How Farh, Stephan Ripke, Felix R. Day, Shaun Purcell, Eli A. Stahl, Sara Lindström, John R. B. Perry, Yukinori Okada, Soumya Raychaudhuri, Mark J. Daly, Nick Patterson, Benjamin M. Neale, Alkes L. Price
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I. Scher, Susan Halabi, Ian F. Tannock, Michael J. Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, Celestia S. Higano, Glenn J. Bubley, Robert Dreicer, Daniel Petrylak, Philip W. Kantoff, Ethan Basch, William Kevin Kelly, William D. Figg, Eric J. Small, Tomasz M. Beer, George Wilding, Alison Martin, Maha Hussain
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney
How much of the research on University of Virginia Cancer Center is open access?
ScholarIQopen access share
83%OPEN ACCESS